Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-low-do...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	William A.E. Parker, Rachel C. Orme, Jessica Hanson, Hannah M. Stokes, Claire M. Bridge, Patricia A. Shaw, Wael Sumaya, Kirstie Thorneycroft, Giovanna Petrucci, Benedetta Porro, Heather M. Judge, Ramzi A. Ajjan, Bianca Rocca, Robert F. Storey
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Taylor & Francis Group 2019-02-01
Reeks:	Platelets
Onderwerpen:	aspirin bleeding p2y12 inhibitors thromboxane ticagrelor
Online toegang:	http://dx.doi.org/10.1080/09537104.2019.1572880
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!